Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers.

Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datasets develop blindspots for these rare variants.

The new platform addresses this limitation by engineering variants at scale and measuring their impact in human cells, generating causal labels that observational datasets can’t create. Pairing this approach with a high-throughput single cell assay ensures that both variant generation and phenotypic readout operate at the same level of scalability, allowing the technologies together to reach further into rare-variant space.

This collaboration has broad implications for biopharma and precision medicine. Researchers will be able to generate causal data, clinicians will be able to access new functional maps for interpreting genomes, and AI teams will be able to use high-dimensional datasets to build more accurate models.

“We are excited to work with Parse on this groundbreaking platform,” says Ryan Gill, PhD, CEO and Co-Founder of Codebreaker Labs. “Together, we are pioneering a new class of genomics data with the potential to impact whole-genome interpretation, target discovery and validation, and even precision clinical trial design.”

“We are pleased to see our technology used for such an important endeavor,” said Charlie Roco, PhD, Chief Technology Officer and Co-founder of Parse Biosciences. “By combining our scalable platform for single cell with Codebreaker’s engineered variant libraries, we can create a unified platform that experimentally determines how thousands of variants influence disease state and progression, and how these rare variants might be more effectively treated in a clinical setting.”